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Fetal  alcohol  spectrum  disorders  (FASDs)  are  the  number  one  cause  of  preventable  men-
tal retardation.  An estimated  2–5%  of  children  are  diagnosed  as  having  a FASD.  While  it
is known  that  children  prenatally  exposed  to alcohol  experience  cognitive  deﬁcits  and a
higher  incidence  of  psychiatric  illness  later  in  life,  the  pathways  underlying  these  abnor-
malities  remain  uncertain.  GSK3  and CDK5  are  protein  kinases  that  are  converging  points
for a vast  number  of signaling  cascades,  including  those  controlling  cellular  processes  criti-
cal to  learning  and memory.  We  investigated  whether  levels  of GSK3  and  CDK5  are  affected
by moderate  prenatal  alcohol  exposure  (PAE),  speciﬁcally  in  the hippocampus  and  medial
frontal  cortex  of  the  adolescent  mouse.  In the present  work  we utilized  immunoblotting
techniques  to demonstrate  that  moderate  PAE  increased  hippocampal  p35  and  -catenin,
and  decreased  total  levels  of GSK3,  while  increasing  GSK3  Ser9  and  Tyr216  phospho-
rylation.  Interestingly,  different  alterations  were  seen in  the  medial  frontal  cortex  where
p35 and  CDK5  were  decreased  and  increased  total GSK3  was  accompanied  by  reduced
Tyr216  of  the  enzyme.  These  results  suggest  that  kinase  dysregulation  during  adolescence
might  be  an  important  contributing  factor  to the  effects  of  PAE  on  hippocampal  and  medial
frontal  cortical  functioning;  and by  extension,  that  global  modulation  of these  kinases  may
produce differing  effects  depending  on  brain  region.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
It has been widely recognized that the in utero envi-
ronment can play a profound role in shaping the health
and  disease susceptibility of the adult [1–3]. During this
exquisitely sensitive developmental period, exposure to
neurotoxic agents can program lasting and sometimes
∗ Corresponding  author at: 1 University of New Mexico, HSC, MSC08
4740, Albuquerque, NM 87131, United States. Tel.: +1 505 272 8811;
fax: +1 505 272 8082.
E-mail  address: aallan@salud.unm.edu (A.M. Allan).
http://dx.doi.org/10.1016/j.toxrep.2014.08.005
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open ac
licenses/by-nc-nd/3.0/).irreversible damage. Fetal alcohol spectrum disorders
(FASDs) generate an array of physiological, behavioral, and
intellectual deﬁcits that persist throughout life with par-
ticularly pronounced damage occurring in the brain [4].
In  a hallmark Center for Disease Control and Prevention
report by Streissguth and colleagues [5], greater than 90%
of  FAS/FASD participants experienced mental health prob-
lems.  The prevalence of FASD, estimated at 2–5% of children
[6],  calls for the continued investigation of how this dam-
age  transpires and the identiﬁcation of potential pathways
that  contribute to perpetuating damage throughout the
lifespan.  Determination of these pathways could provide
novel therapeutic options and potentially decrease the
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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ater development of comorbid disease states including
epression, anxiety disorders, bipolar disorder, and sub-
tance  abuse [7–12].
Using  a mouse model of moderate prenatal alcohol
xposure (PAE), we have previously identiﬁed disrupted
orticosteroid signaling systems in both the medial frontal
ortex  (mFC) and hippocampus (HPC) of adolescent PAE
ffspring [13,14]. Corticosteroid signaling includes activa-
ion  of glucocorticoid receptors (GR) and mineralocorticoid
eceptors (MR) and has been demonstrated to be highly
nvolved in learning and memory processes [15–18], sug-
esting  that dysregulation within brain corticosteroid
ignaling may  contribute to the intellectual impairment
fter PAE. Curiously, the PAE-induced damage to corti-
osteroid signaling seems to be speciﬁc to discrete brain
egions; nuclear levels of GR are increased in the hippocam-
us  with a corresponding increase in trafﬁcking machinery,
hereas in the frontal cortex, nuclear accumulation of GR
s  decreased in conjunction with a decrease in the respec-
ive  trafﬁcking proteins [13,14]. The signaling cascades that
irect  GR trafﬁcking alterations in these brain regions after
AE  are currently unknown.
Corticosteroid  signaling is regulated in part by ser-
ne/threonine kinases, including cyclin-dependent kinase 5
CDK5)  and glycogen synthase kinase-3 (GSK3) [19–23].
hese kinases orchestrate various cellular functions includ-
ng  neuronal maturation, neurotransmitter release, axon
nd  dendritic organization, neural trafﬁcking, transport,
nd  signal transduction [24–26]; both are implicated in
he  progression of several major psychiatric illnesses and
eurodegenerative diseases [27–29]. Studies have shown
hat  GSK3 and CDK5 are responsive to alcohol [30–32],
lthough the effects generated by a moderate in vivo pre-
atal  exposure and the duration of such effects remain
nclear. GSK3 and CDK5 can also regulate GR protein
tability, subcellular localization, protein interactions, and
ranscriptional targeting [22,33–35], making these kinases
ntriguing targets for the investigation of PAE-mediated
amage. Based on our previous observations, we sought
o  investigate the effects of PAE on CDK5 and GSK3 dur-
ng  adolescence. Dysregulated signaling within the GSK3
nd  CDK5 pathways could be mechanistically related to
he  GR deﬁcits and could also underlie some of the cog-
itive  and behavioral deﬁcits reported in our PAE model.
n  the present work, we evaluated CDK5, its activator p35,
-catenin,  and GSK3 along with its Ser9 and Tyr216 phos-
horylated states in both the mFC  and HPC of adolescent
ice prenatally exposed to alcohol. To our knowledge, this
s  the ﬁrst study to use an in vivo model to demonstrate that
oderate  PAE alters the expression of these critical signal-
ng  proteins during the dynamic period of adolescence.
. Materials and methods
.1.  Prenatal alcohol exposure
All  procedures were performed in accordance with
he University of New Mexico Institutional Animal Care
nd  Use Committee (IACUC) guidelines. The limited-
ccess PAE was conducted as described previously [36].
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maintained on a reverse light/dark cycle (lights off at 0800 h
and  on at 2000 h) with food and water ad libitum in a
temperature controlled facility. Females were assigned to
either  a PAE group (10% (w/v) ethanol in 0.066% saccharin)
or  a 0.066% saccharin control group (SAC). Water bottles
were  removed and females were provided with access
to  the respective solution from 1000 h to 1400 h daily.
Drinking began prior to pregnancy and was maintained
until parturition, at which point alcohol was  withdrawn
using a step-down procedure over 6 days. This model of
drinking  produces average blood alcohol concentrations
of ∼90 mg/dL at the end of the four hour drinking period
[36,37].
2.2. Sample collection
PAE  and SAC offspring were weaned at ∼postnatal day
(PND) 23 and housed with same-sex littermates. At PND
40–50,  male offspring were sacriﬁced by decapitation and
the  HPC and mFC  were rapidly dissected on ice. The mFC
area  was deﬁned as the cingulate, infralimbic and prelimbic
regions combined [13]. Tissue samples were snap-frozen in
liquid  nitrogen and stored at −80 ◦C until tissue processing.
2.3. Tissue homogenization
The  HPC and mFC  were homogenized in a buffer
containing 20 mM Tris–HCl, pH7.4, 1 mM EDTA, 320 mM
sucrose, 20 mM  -glycerophosphate, 20 mM  sodium
pyrophosphate, 10 mM sodium ﬂuoride, 200 M sodium
orthovanadate, and protease inhibitor cocktail (1:1000,
Sigma–Aldrich, St. Louis, MO). The homogenate was  cen-
trifuged at 1000× g for 6 min  at 4 ◦C. The supernatant was
collected and the pellet was  washed in the homogenization
buffer and centrifuged again. The second supernatant was
collected  and combined with the ﬁrst, producing a “post-
nuclear lysate” which was used in the following protein
analysis.
2.4.  Immunoblotting
Target proteins were assessed in the HPC and mFC
using standard Western immunoblotting techniques as
described  in [13]. An N = 6–7 PAE and SAC samples were
run on the same blot for each protein. Tissue homogenate
was diluted in NuPAGE® LDS Sample Buffer (#NP0007,
InvitrogenTM, Grand Island, NY), heated for 10 min  at 70◦,
loaded  into 4–12% Bis–Tris gels (#NP0336, InvitrogenTM)
and  electrophoresed for 1.5 h at 165 V (15 g total pro-
tein for GSK3 and -catenin, 20 g for CDK5 and p35,
10 g for pGSK3 Ser9 and pGSK3 Tyr216). For CDK5,
-catenin, GSK3, and p35, protein was  transferred to
PVDF membranes (#162-0177, Bio-Rad Laboratories, Her-
cules,  CA) for 1 h at 40 V. Membranes were blocked in
Tropix I-BLOCK (#T2015, Applied Biosystems, Grand Island,
NY)  for 1 h. Blots were then washed in TBST and incu-
bated overnight at 4 ◦C with primary antibody diluted in
I-BLOCK  (GSK3: Santa Cruz Biotechnology, Santa Cruz,
CA,  #sc-7291, 1:1000, p35: Santa Cruz Biotechnology, #sc-
820,  1:1000, CDK5: Santa Cruz Biotechnology, #sc-173,
1:1000, -catenin: Santa Cruz Biotechnology, #sc-7963,
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mpus. (A
E (N = 7)Fig. 1. Prenatal alcohol exposure alters p35 but not CDK5 in the hippoca
saccharin  controls (N = 7). B). CDK5 was  unchanged (p > .05) between PA
shown  below each ﬁgure. All data are mean ± SEM.
1:1000). Membranes were incubated in goat anti-rabbit
or goat anti-mouse secondary antibody solution (#31460,
Pierce, Rockford, IL 1:30,000), detected with Western
Lightning Plus-ECL developing solution (#NEL105001EA;
Perkin Elmer, Waltham, MA)  and exposed to x-ray
ﬁlm (#F-BX57, Phenix Research Products, Candler, NC).
Immunoreactivities were quantiﬁed using Quantity One
1-D  Analysis Software (Bio-Rad Laboratories). For both
phosphoisoforms of GSK3, proteins were transferred to
Immobilon-FL membranes and blocked with OdysseyTM
Blocking Buffer (#927-40000, LI-COR Biosciences, Lincoln,
NE).  Primary antibodies (GSK3 216: #GM1321, ECM Bio-
sciences, Versailles, KY, 1:1000: GSK3 Ser9, #D85E12, Cell
Signaling,  Danvers, MA  1:1000) were detected using IRDye
680RD  goat anti-mouse (#926-68070, LI-COR Biosciences,
1:10,000) or 800CW goat anti-rabbit (#926-32211, LI-
COR  Biosciences, 1:10,000). Blots were scanned using
two-channel infrared direct detection (Odyssey Imaging
System, LI-COR Biosciences) and quantiﬁed using Image
Studio (version 3.1 LI-COR Biosciences).
2.5. Coomassie staining
Coomassie  staining was performed as a within-lane
loading control as described in our previous publications
[13,14]. After immunodetection, membranes were stained
with  Coomassie Brilliant Blue R-250 (Bio-Rad; #161-0400)
and  quantiﬁed using Quantity One Software (Bio-Rad Lab-
oratories).  The target protein signal for each lane was
corrected against the Coomassie stain for each lane to
account for any possible loading discrepancies.
2.6. Statistical analysisAll  data were analyzed by Student’s t-test using Graph-
pad  PRISM® Software vs. 6.03. Statistical signiﬁcance was
set  at p < .05 and sample size was deﬁned as the number of) p35 was signiﬁcantly increased (*p = .0027) in PAE (N = 6) compared to
 and saccharin controls (N = 7). Representative Western blot images are
animals  sampled in each condition, each from a different
litter
3.  Results
3.1. Prenatal alcohol exposure alters p35 but not CDK5
protein in the hippocampus
To  determine the effect of PAE on the protein expres-
sion of both CDK5 and its activator, p35, we performed
Western immunoblotting on hippocampal tissue. CDK5
activity has been documented to be correlated with lev-
els  of expression of p35 [38]. A signiﬁcant increase in p35
was  observed in PAE offspring compared to SAC controls
(Fig. 1); t(11) = 3.85, p = .0027. CDK5 protein was unaltered
in  PAE compared to SAC controls (Fig. 1); t(12) = 0.8495,
p  > .05.
3.2. Prenatal alcohol exposure alters both p35 and CDK5
in  the medial frontal cortex
Next,  we examined whether PAE would have the same
effect on CDK5 and p35 in the mFC  as in the HPC. CDK5
and its activator have been demonstrated to play impor-
tant  roles in both of these regions [39,29]. We performed
Western immunoblotting for CDK5 and p35 protein in mFC
samples  from both PAE and SAC controls. We  found that
p35  was  decreased in PAE mFC compared to SAC controls
(Fig.  2); t(12) = 3.064, p = .0098, showing an opposite ﬁnd-
ing  from the HPC. Interestingly, CDK5 protein was  also
decreased in the mFC  in PAE compared to SAC controls
(Fig. 2); t(11) = 4.263, p = .0013.
3.3. Prenatal alcohol exposure decreases GSK3  ˇ in the
hippocampus andaltersGSK3  ˇ phosphorylation
GSK3 is a constitutively active enzyme that is
controlled primarily through inhibitory phosphorylation.
S.L. Goggin et al. / Toxicology Reports 1 (2014) 544–553 547
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Gig. 2. Prenatal alcohol exposure decreases both p35 and CDK5 protein i
N  = 7) compared to saccharin controls (N = 7). (B) CDK5 protein is also si
N  = 6). Representative Western blot images are shown below. All data are
hosphorylation at the Tyr216 site is necessary for opti-
al  activity, while phosphorylation on the Ser9 residue
nactivates the kinase [40]. GSK3 has also been reported
o  be phosphorylated at Thr43 and Ser389 which are
uggested to increase Ser9 phosphorylation [41,42]. To
etermine the effect of PAE on GSK3 in the HPC, we
easured total GSK3 and levels of phosphorylation at
oth  Ser9 and Tyr216. Western immunoblotting showed
 signiﬁcant decrease in the total (both unphosphorylated
nd phosphorylated isoforms) levels of GSK3 (Fig. 3A);
(12)  = 3.220, p = .0074. Analysis of phosphorylated GSK3
soforms revealed an increase in Ser9 phosphorylation
Fig. 3B), p = .038. As this comparison resulted in a signif-
cant  Levene’s test [F(12) = 5.4, p = .04], a Mann–Whitney
est was used for the post hoc test. There was also an
ncrease in phospho-Tyr216 GSK3 in PAE mice (Fig. 3C),
(12)  = 2.22, p = .046.
.4. Prenatal alcohol exposure increases GSK3  ˇ in the
edial frontal cortex and increases Ser9 but not Tyr216
hosphorylation
We  also investigated whether PAE would have a similar
ffect on GSK3 and its phosphorylation in the mFC. PAE
igniﬁcantly increased total GSK3 expression in the mFC
ompared to SA/C controls (Fig. 4A); t(12) = 3.593, p = .0037,
howing  an opposite ﬁnding from the HPC. There was no
hange  in Ser9 phosphorylation levels (Fig. 4B), t(12) = 1.20,
 > .05, while the level of phospho-Tyr216 was signiﬁcantly
ecreased (Fig. 4C), t(11) = 3.22, p = .008.
.5.  Prenatal alcohol exposure increases ˇ-catenin in the
ippocampus but not medial frontal cortexBoth CDK5 and GSK3 play regulatory roles in -catenin
ignaling. CDK5 can bind to -catenin and regulate its inter-
ction  with scaffolding molecules [43–45], while increased
SK3 can target -catenin for degradation [46]. Thus,edial frontal cortex. (A) p35 is signiﬁcantly decreased (*p = .0098) in PAE
tly decreased (**p = .0013) in PAE (N = 7) compared to saccharin controls
sed as mean ± SEM.
we  measured -catenin levels in both the HPC and mFC
to  determine if the PAE-induced changes in p35/CDK5
and GSK3 would affect this particular substrate. In the
HPC  of PAE mice, we observed a signiﬁcant increase in -
catenin  compared to SAC controls (Fig. 5); t(11) = 2.480,
p  = .0306, although there was no signiﬁcant change in the
mFC  t(12) = 0.1099, p > .05.
4. Discussion
Alterations in GSK3 levels and activity have been asso-
ciated with neurogenesis, mood disorders, and learning
and  memory [31]. While not a part of the present study,
previous work with our PAE model has found deﬁcits in
neurogenesis [47] increased depressive behavior [48] and
learning  deﬁcits [36]. Although the existing literature sug-
gests  that CDK5 and GSK3 contribute to behavioral and
cognitive functioning, their roles in PAE-associated impair-
ments  in these processes are unknown. Furthermore, the
possibility of regional speciﬁcity of PAE-induced changes
in  CDK5 and GSK3 is not fully understood. In the present
work, we  began to address these issues utilizing an in vivo
model  of moderate PAE to identify alterations in CDK5 and
GSK3  in the adolescent HPC and mFC. It is noteworthy
that we assessed effects manifested during adolescence,
as developmentally signiﬁcant time points, such as ado-
lescence, are frequently neglected in studies that employ
in  vivo animal models of PAE.
These ﬁndings demonstrate that moderate PAE pro-
duces region-speciﬁc alterations in p35, CDK5, -catenin,
and  GSK3 and its phosphorylation in adolescent male off-
spring.  In the HPC, the p35 activator of CDK5 was  increased
although no change in total CDK5 was noted (Fig. 1). Work
by  Ou and colleagues determined that CDK5 activity cor-
relates  with p35 expression instead of CDK5 expression
[38] and, thus, the increased p35 levels in the PAE mouse
HPC  could produce aberrantly high levels of CDK5 activity
in  this brain region. Our p35 ﬁnding is consistent with a
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Fig. 3. Prenatal alcohol exposure alters GSK3 total protein as well as Ser9 and Tyr216 phosphorylation in the hippocampus. (A) Total GSK3 protein was signiﬁcantly decreased (**p = .0074) in prenatal alcohol
exposure  (PAE, N = 7) compared to saccharin controls (SAC, N = 7) mouse hippocampus. (B) Phosphorylation of GSK3 Ser9 was signiﬁcantly increased (*p = .038) in PAE (N = 7) compared to SAC (N = 7). (C)
Phosphorylation  of GSK3 Tyr216 was  also increased (*p = .046) in PAE (N = 7) compared to SAC (N = 7). Representative Western images are shown below for each. All data are expressed as mean ± SEM.
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Fig. 4. Prenatal alcohol exposure increases GSK3 total protein and decreases GSK3 Tyr216phosphorylation in the medial frontal cortex. (A) Total GSK3
protein  is signiﬁcantly increased (**p = .0037) in prenatal alcohol exposure (PAE, N = 7) compared to saccharin controls (SAC, N = 7) mouse medial frontal
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(ortex.  (B) Phosphorylation of GSK3 at the Ser9 was not different betwee
as  decreased (**p = .008, >.05) in PAE (N = 6) compared to SAC (N = 7) m
xpressed  as mean ± SEM.
eport by Li and colleagues [49] that shows PAE increases
35 protein in the HPC of adult rats. This study also found
hat  PAE increases CDK5 in the HPC; although we  did
ot  ﬁnd CDK5 protein to be altered in the HPC in our
ouse model, the difference between the studies’ results
ay  be due to differences in alcohol exposure levels and
outes  of administration, with their 25% (w/v) intragastric
avage being much higher than our 10% (w/v) voluntary
rinking paradigm. Our study shows that even moderate
mounts of ethanol possess the neurotoxic potential to
lter  p35 expression much later in life. Total GSK3 pro-
ein  was decreased by PAE in the HPC (Fig. 3). In conjunction
ith this, increased phosphorylation at the inhibitory Ser9
esidue  of GSK3 was observed, while phosphorylation of
he  activating Tyr216 residue was also increased. The effect
ig. 5. Prenatal alcohol exposure increases -catenin in the hippocampus but not
*p  = .0306) in PAE (N = 7) compared to saccharin controls (N = 6). (B) -Catenin is u
N  = 7). Representative Western blot images are shown below for each. All data isN = 7) and SAC (N = 7) mice. (C) Phosphorylation of GSK3 Tyr216 residue
resentative Western blot images are shown below for each. All data are
of  these changes on GSK3 catalytic activity was  not deter-
mined  in our studies but is it likely that it is reduced, as total
enzyme  levels were reduced and GSK3 is a constitutively
active kinase that is primarily regulated by inhibition at
Ser9  [50]. Taken together, these ﬁndings show that regu-
lation  of CDK5 and GSK3 is shifted in favor of decreased
GSK3 and increased p35 in the PAE adolescent HPC.
In  contrast to the HPC protein changes, both p35 and
CDK5 were decreased in the mFC  (Fig. 2). Decreases in
these  protein levels show that PAE is altering protein con-
tent  in a direction consistent with decreased CDK5 activity.
Total  GSK3 protein was increased and Tyr216 phospho-
rylation was decreased (Fig. 4). The effect of these changes
on  GSK3 activity was not measured in these studies but
it  is likely that the increased GSK3 levels are associated
 medial frontal cortex. (A) -Catenin is signiﬁcantly increased in the HPC
nchanged in the mFC  (p > .05) between PAE (N = 7) and saccharin controls
 expressed as mean ± SEM.
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cts p35,
 adolescFig. 6. Summary of ﬁndings: prenatal alcohol exposure differentially affe
Tyr216  phosphorylation in the hippocampus and medial frontal cortex of
with a relative increase in the amount of GSK3 activity
present in the cell, as inhibitory regulation was not altered;
however, the reduction in Tyr216 phosphorylation may, in
part,  compensate for the increase in total GSK3 protein.
Liu and colleagues [51] have reported that acute treatment
(two doses of 2.5 g ethanol/kg, separated by 2 h) of 7-day-
old  mice with ethanol was associated with reduced GSK3
Ser9  phosphorylation with little effect on the level of total
GSK3  or Tyr216 phosphorylation of the enzyme in the
cerebral cortex. Acute alcohol treatment paradigms like
that  in the Liu study have been demonstrated to increase
cell  death through increasing GSK3b. Differences between
our  results and those of these investigators are likely due to
differences  in the treatment paradigm (exposure through-
out  gestation vs. acute postnatal treatment), the age of
testing  of the animals (adolescence vs. postnatal day 7) and
the  tissue assayed (isolated medial frontal cortex vs. whole
cerebral  cortex). The rise in total protein levels of GSK3
occurs in conjunction with a decrease in p35 and CDK5 lev-
els  in the mFC, which is opposite from the decrease in total
GSK3  and increase in p35 in the HPC (Fig. 6). Interestingly,
CDK5 and GSK3 have been shown to inversely regu-
late each other. Deleting the p35 gene, the predominant
CDK5 activator [52], increases GSK3 and redirects GSK3
gene  targeting [25]. Other studies have also described the
cross-talk  between CDK5 and GSK3 [53–55]. Our results
demonstrate that protein regulation is shifted toward p35
and  away from GSK3 expression in the HPC, but toward
GSK3 expression and away from p35/CDK5 in the mFC
(Fig.  6). This could have important implications for thera-
peutic  interventions that utilize global up/down regulation
of  target proteins since our ﬁndings identify regional speci-
ﬁcity  in PAE alterations; pharmacological inhibition of one CDK5, -catenin, total GSK3, GSK3 Ser9 phosphorylation, and GSK3
ent male offspring.
of  these kinases might also redirect the targeting of the
other  kinase.
Both  CDK5 and GSK3 can modulate -catenin sig-
naling; this regulation is complex, however, and depends
on  other kinases to prime the substrate as well as scaf-
folding proteins to successfully link the kinase with the
substrate [56]. -Catenin performs various important cel-
lular  functions that range from cytoskeletal structuring to
intracellular signaling [57]. Bath application for 96 h of 20
and  100 mM ethanol to neural stem cells derived from
human fetal brains produced a decrease in the expression
of  -catenin [32]. Our results of increased -catenin in the
HPC  of adolescent PAE mice are interesting in light of the
Vangipuram and Lyman study in that the observed increase
could  reﬂect a compensatory upregulation of -catenin
that occurs following PAE. The increase in HPC -catenin
in  contrast with unchanged -catenin in the mFC  (Fig. 5)
might  imply that the effects of PAE on adolescent -catenin
are  subject to additional regulatory mechanisms that differ
between  these brain regions, including scaffolding proteins
such  as presenilin and axin [44,46]. More work should be
done  to determine the developmental changes of -catenin
in  response to PAE.
It  is of particular interest that PAE-associated changes
differ in the HPC and the mFC; that is; PAE produced
differential regulation of the target proteins depending
on the brain region examined. GSK3 total protein was
decreased in the HPC and increased in the mFC, while p35
was  increased in the HPC and decreased in the mFC  (Fig. 6).
This  parallels our previous ﬁnding of decreased nuclear GR
in  the mFC  [13] and increased nuclear GR in the HPC [14].
It  is unclear as to why  PAE differentially regulates these
proteins in the HPC and mFC, but may  be related to the
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istinct function of these brain structures in cognitive pro-
esses.  The GR is known to play important roles in both of
he  regions, although GR signaling differs regionally. Work
y  Kitchener and colleagues determined that GR binding
o  glucocorticoid response element sites is longer lasting
nd  of higher amplitude in the HPC than in the frontal
ortex [58]. Similarly, prenatal stress has been shown to
ncrease  GSK3 protein in the frontal cortex but not in the
PC,  and the authors conclude that GSK3 could be a target
f  the maladaptive glucocorticoid action on frontal cortex
eurons [59]. Because GSK3 and CDK5 play roles in the
egulation of GR signaling [20,22,60], we speculate that
hese  changes in PAE could be functionally related. Future
ork  from our laboratory will aim to elucidate this rela-
ionship.
One  interpretation of these ﬁndings is that PAE alters the
evelopmental trajectories compared to age-matched con-
rols.  Adolescence is a period of rapid brain development
n which subtle variances may  affect later brain structure
nd function [61,62]. Beurel and colleagues present the
nteresting ﬁnding that GSK3 has speciﬁc developmen-
al regulation that greatly differs between the adolescent
nd adult brain. Using C57BL/6 J mice, they demonstrate
hat there are large increases in HPC GSK3 levels between
ND1 and the juvenile period followed by decreased levels
n  adolescence and an even further decrease once adult lev-
ls  are reached by eight weeks [63]. Their work also showed
hat  Ser9 phosphorylation is higher in the juvenile mouse
nd  decreases steadily until adult levels are reached; how-
ver,  treatment with lithium or ﬂuoxetine did not show
he  robust increase in Ser9 phosphorylation for adolescents
hat it does for adult mice, proving that these mood stabiliz-
rs  do not exert the same effects on adolescent GSK3 as in
dults  [63]. The PAE mice have increased Ser9 phosphory-
ation of GSK3 compared to controls in the HPC, indicating
hat  this kinase is being regulated differently than age-
atched controls in this brain region. The changes that we
bserve  in GSK3 phosphorylation and total GSK3 levels
ould  be indicative of differing developmental trajectories
etween PAE and control brains. The ﬁndings of Beurel et al.
63]  reveal that many of these kinases undergo a great deal
f  ﬂuctuation during different developmental points. Thus,
hile  several studies indicate that reductions in GSK3 are
europrotective, it is difﬁcult to draw this conclusion in all
rain  regions and at all developmental time points. Relative
o  the present study where ethanol exposure occurs prena-
ally,  GSK3 deletion results in a hyperproliferation of neural
rogenitors which, in turn, results in a suppression of post-
itotic  neurons and a dysregulation of signaling pathways
ritical for brain development, including -catenin [64].
his  suggests that GSK3 beta activity is necessary for nor-
al  brain processes and that it’s important that it is at the
ight  level of activity at the right time.
Abnormalities in both CDK5 and GSK3 are well docu-
ented in numerous mood disorders as well as addiction
65–69]. Work by Famy and colleagues [7] found that
ndividuals prenatally exposed to alcohol have a higher
isk  of developing psychopathology including alcohol/drug
ependence, major depression, and other psychiatric dis-
rders.  Multiple signaling pathways converge upon both
SK3  and CDK5 and changes to these kinases could haveorts 1 (2014) 544–553 551
far-reaching downstream effects, especially during adoles-
cent  brain development. As 75% of mental illness cases
manifest by age 25, adolescence represents a critical devel-
opmental window in this process [70]. More work should
be  done to determine the effects of altered GSK3 and CDK5
protein  in the PAE adolescent brain. Prenatal insults such
as  PAE that change kinase balance during this time could
potentially be related to later development of psychiatric
illness and neurodegenerative diseases.
5. Conclusions
The ﬁndings from this work are an important ﬁrst step
in  determining the age-dependent regulation of CDK5 and
GSK3  by moderate PAE. CDK5 and GSK3 are currently
drug targets in a number of psychiatric and neurodegenera-
tive illnesses [71,72] and understanding how these kinases
change during different developmental stages will provide
important information with respect to PAE-related deﬁcits.
The  adolescent to adult transition is a time period that is
still  inadequately understood in the PAE ﬁeld and might
have  important consequences for the development of and
susceptibility to later disease.
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